{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:13:26Z","timestamp":1770974006899,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1124\/dmd.108.025494","type":"journal-article","created":{"date-parts":[[2009,9,23]],"date-time":"2009-09-23T02:44:16Z","timestamp":1253673856000},"page":"2330-2339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator"],"prefix":"10.1016","volume":"37","author":[{"given":"Lilly","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L.","family":"Skiles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magang","family":"Shou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.108.025494_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-3565(25)24810-8","article-title":"Selective inhibition of warfarin metabolism by diltiazem in humans","volume":"257","author":"Abernethy","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.025494_bib2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1124\/dmd.105.005579","article-title":"Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis","volume":"33","author":"Atkinson","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.104.002436","article-title":"The binding of drugs to hepatocytes and its relationship to physicochemical properties","volume":"33","author":"Austin","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1994.tb04266.x","article-title":"Dose of midazolam should be reduced during diltiazem and verapamil treatments","volume":"37","author":"Backman","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/00912700022009152","article-title":"Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition","volume":"40","author":"Bauer","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.phrs.2003.10.010","article-title":"Pharmacokinetic interactions between omeprazole\/pantoprazole and clarithromycin in health volunteers","volume":"49","author":"Calabresi","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.108.025494_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/002215540205000514","article-title":"The fluorescent probe Bodipy-FL-verapamil is a substrate for both P-glycoprotein and multidrug resistance-related protein (MRP)-1","volume":"50","author":"Crivellato","year":"2002","journal-title":"J Histochem Cytochem"},{"key":"10.1124\/dmd.108.025494_bib8","first-page":"1257","article-title":"Comparison of different approaches to predict metabolic drug-drug interactions","volume":"37","author":"Einolf","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.108.025494_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1124\/dmd.107.019265","article-title":"CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles","volume":"36","author":"Foti","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib10","first-page":"776","article-title":"Cyclosporin-erythromycin interaction in normal subjects","volume":"23","author":"Freeman","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0009-9236(99)70034-2","article-title":"Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans","volume":"66","author":"Furuta","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib12","first-page":"35","article-title":"The pharmacological and pharmacokinetic properties of troleandomycin","author":"Genazzani","year":"1975","journal-title":"Quad Antibiot"},{"key":"10.1124\/dmd.108.025494_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/138920006776359293","article-title":"A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation","volume":"7","author":"Ghanbari","year":"2006","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.108.025494_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0009-9236(95)90067-5","article-title":"The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine","volume":"58","author":"Gomez","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0009-9236(98)90176-X","article-title":"Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences","volume":"64","author":"Greenblatt","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0009-9236(98)90172-2","article-title":"Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences","volume":"64","author":"Greenblatt","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1124\/mi.3.4.194","article-title":"Cytochromes P450, drugs, and diseases","volume":"3","author":"Guengerich","year":"2003","journal-title":"Mol Interv"},{"key":"10.1124\/dmd.108.025494_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2125.1988.tb03320.x","article-title":"Erythromycin enhances the absorption of cyclosporin","volume":"25","author":"Gupta","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0091270005284854","article-title":"Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin","volume":"46","author":"Gurley","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib20","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.39.9.2078","article-title":"Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state","volume":"39","author":"Gustavson","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.108.025494_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/0049825021000023996","article-title":"Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent","volume":"33","author":"He","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.108.025494_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/bdd.488","article-title":"The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers","volume":"27","author":"Hedaya","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.108.025494_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/j.1552-4604.1992.tb03823.x","article-title":"Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine","volume":"32","author":"Hermann","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.108.025494_bib25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1124\/dmd.31.7.945","article-title":"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes","volume":"31","author":"Ito","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib26","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1124\/dmd.108.025494_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1515\/DMDI.2000.16.3.207","article-title":"Effect of clarithromycin on the pharmacokinetics of tolbutamide","volume":"16","author":"Jayasagar","year":"2000","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1124\/dmd.108.025494_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0009-9236(98)90151-5","article-title":"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations","volume":"64","author":"Kantola","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0090-9556(25)08097-3","article-title":"Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes","volume":"21","author":"Kim","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1042\/BJ20050433","article-title":"Alamethicin permeabilizes the plasma membrane and mitochondria but not the tonoplast in tobacco (Nicotiana tabacum L. cv Bright Yellow) suspension cells","volume":"389","author":"Matic","year":"2005","journal-title":"Biochem J"},{"key":"10.1124\/dmd.108.025494_bib32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0090-9556(24)15182-3","article-title":"An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation","volume":"28","author":"Mayhew","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.32.10.1083","article-title":"Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs","volume":"32","author":"McConn","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib34","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/0002-9149(85)90987-7","article-title":"Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol","volume":"55","author":"McLean","year":"1985","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"10.1124\/dmd.108.025494_bib35","first-page":"37S","article-title":"The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers","volume":"53","author":"Muirhead","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.1991.tb05536.x","article-title":"Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects","volume":"31","author":"Murdoch","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.clpt.2005.09.004","article-title":"In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach","volume":"78","author":"Obach","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/clpt.1993.25","article-title":"A potentially hazardous interaction between erythromycin and midazolam","volume":"53","author":"Olkkola","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004714-198610000-00008","article-title":"A pharmacokinetic drug interaction between erythromycin and triazolam","volume":"6","author":"Phillips","year":"1986","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.108.025494_bib41","first-page":"505","article-title":"A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans","volume":"70","author":"Phimmasone","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib42","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1124\/jpet.104.071803","article-title":"Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro","volume":"311","author":"Polasek","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.025494_bib43","first-page":"465","article-title":"Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes","volume":"57","author":"Rodrigues","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib44","first-page":"623","article-title":"Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily","volume":"25","author":"Rodrigues","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003088-199937050-00003","article-title":"Clinical pharmacokinetics of clarithromycin","volume":"37","author":"Rodvold","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.108.025494_bib46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo drug metabolism in human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.108.025494_bib47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-5793(93)81540-G","article-title":"P-glycoprotein-mediated transcellular transport of MDR-reversing agents","volume":"324","author":"Saeki","year":"1993","journal-title":"FEBS Lett"},{"key":"10.1124\/dmd.108.025494_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/clpt.1988.108","article-title":"Effect of calcium channel blockers on theophylline disposition","volume":"44","author":"Sirmans","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/j.1875-9114.1996.tb02949.x","article-title":"Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction","volume":"16","author":"Sketris","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.108.025494_bib50","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0022-3565(24)36788-6","article-title":"Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites","volume":"282","author":"Sutton","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.025494_bib51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0014-2999(98)00607-4","article-title":"Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells","volume":"358","author":"Takano","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib52","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib53","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2125.1999.00923.x","article-title":"Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil","volume":"47","author":"Tracy","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-2952(97)00239-6","article-title":"In vitro approaches to predicting drug interactions in vivo","volume":"55","author":"von Moltke","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00007691-198703000-00022","article-title":"Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient","volume":"9","author":"Wadhwa","year":"1987","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.108.025494_bib56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2125.1997.00649.x","article-title":"Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A","volume":"44","author":"Wang","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib57","first-page":"502","article-title":"Human cytochrome P450 3A4-catalyzed testosterone 6\u03b2-hydroxylation and erythromycin N-demethylation. Competition during catalysis","volume":"25","author":"Wang","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib58","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00543975","article-title":"Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation","volume":"32","author":"Warot","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib59","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0090-9556(24)15373-1","article-title":"CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes","volume":"28","author":"Wester","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.025494_bib60","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0269881106065907","article-title":"Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA","volume":"20","author":"Yang","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1124\/dmd.108.025494_bib61","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.108.025494_bib62","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.108.025494_bib63","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0009-9236(96)90179-4","article-title":"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism","volume":"59","author":"Yasui","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib64","first-page":"400","article-title":"Interaction between midazolam and clarithromycin: comparison with azithromycin","volume":"34","author":"Yeates","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.025494_bib65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2125.2001.01386.x","article-title":"Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes","volume":"51","author":"Yeo","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.108.025494_bib66","first-page":"213","article-title":"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam","volume":"46","author":"Zimmermann","year":"1996","journal-title":"Arzneimittelforschung"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624022323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624022323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.108.025494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:45:50Z","timestamp":1739897150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624022323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0090955624022323"],"URL":"https:\/\/doi.org\/10.1124\/dmd.108.025494","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.108.025494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}